Temozolomide
- Generic Name
- Temozolomide
- Brand Names
- Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C6H6N6O2
- CAS Number
- 85622-93-1
- Unique Ingredient Identifier
- YF1K15M17Y
- Background
Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...
- Indication
Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.
- Associated Conditions
- Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome
- Associated Therapies
- -
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2022-12-29
- Lead Sponsor
- Kari Kendra
- Target Recruit Count
- 30
- Registration Number
- NCT05588453
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Surgical Pembro +/- Olaparib w TMZ for rGBM
- Conditions
- Interventions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- L. Nicolas Gonzalez Castro, MD, PhD
- Target Recruit Count
- 78
- Registration Number
- NCT05463848
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 45
- Registration Number
- NCT05440786
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸The Regents of the University of California - Los Angeles (UCLA Pediatrics), Los Angeles, California, United States
🇺🇸Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States
Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Seoul National University Boramae Hospital
- Target Recruit Count
- 268
- Registration Number
- NCT05439278
Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
- Conditions
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 190
- Registration Number
- NCT05432791
- Locations
- 🇺🇸
Epic Care-Dublin, Dublin, California, United States
🇺🇸Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 97
- Registration Number
- NCT05432804
- Locations
- 🇺🇸
University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
🇺🇸Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 231
- Registration Number
- NCT05429502
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸St Jude s Childrens Research Hospital, Memphis, Tennessee, United States
🇺🇸Cohen Children's Medical Center of New York, New Hyde Park, New York, United States
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 490
- Registration Number
- NCT05417594
- Locations
- 🇬🇧
Research Site, Newcastle Upon Tyne, United Kingdom
Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)
- Conditions
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Centre Oscar Lambret
- Target Recruit Count
- 28
- Registration Number
- NCT05384821
- Locations
- 🇫🇷
CHU de MONTPELLIER - Hôpital Arnaud de Villeneuve, Montpellier, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷CHRU NANCY - Hôpital d'Enfants, Vandœuvre-lès-Nancy, France
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 198
- Registration Number
- NCT05247905
- Locations
- 🇺🇸
Advocate Outpatient Center - Aurora, Aurora, Illinois, United States
🇺🇸Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States
🇺🇸MU Health Care Goldschmidt Cancer Center, Jefferson City, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.